From October 24 to 26, 2023, sponsored by Shanghai Biomedical Science and Technology Development Center, Shanghai Fengxian District Science and Technology Commission, Shanghai Fengxian District Economic Commission, Shanghai Industrial Comprehensive Development Zone Co., Ltd., National Engineering Research Center for Standardization Technology of Traditional Chinese Medicine, Shanghai Biomedical Public Technology Service Co., Ltd The 16th Shanghai International Conference on Traditional Chinese Medicine and Natural Medicines (STCM 2023), hosted by the Science and Technology Development Promotion Center of Fengxian District, Shanghai and Shanghai Science and Technology Exhibition Co., Ltd., was grandly held in Fengxian District, Shanghai.

The Shanghai International Conference on Traditional Chinese Medicine and Natural Medicines is an important platform for promoting the integration and interaction of traditional Chinese medicine technology innovation and industrial development in Shanghai, and has become one of the most influential high-end professional events in the field of traditional Chinese medicine and natural medicines. The 16th Shanghai International Conference on Traditional Chinese Medicine and Natural Medicines mainly focuses on "innovation in traditional Chinese medicine, regional cooperation, and high-quality development", focusing on innovation hotspots, cutting-edge trends, policies and regulations, and regional cooperation in the field of traditional Chinese medicine. Combining the industrial advantages and characteristics of traditional Chinese medicine in Fengxian District, nearly 500 Chinese and foreign academicians, renowned experts and scholars, enterprise elites, and government officials from the field of traditional Chinese medicine and natural medicines were invited to present their conference reports Conduct discussions through thematic reports, discussions, and exchanges.

The opening ceremony was presided over by Li Jizong, director of the Shanghai Biomedical Science and Technology Development Center. Zhu Qigao, deputy director of the Shanghai Municipal Science and Technology Commission, Chen Yongzhang, chairman of the Fengxian District CPPCC, Shen Jianzhong, deputy director of the China Biotechnology Development Center, and Chen Kaixian, researcher of the Chinese Academy of Sciences Shanghai Institute of Materia Medica, delivered speeches respectively. This conference has held one closed door meeting, one opening ceremony, and four sub meeting reports, focusing on the safety of traditional Chinese medicine, research and development of traditional Chinese medicine, active substances, new drug creation, transformation of traditional Chinese medicine preparations, quality control and supervision of traditional Chinese medicine, and innovative technologies of traditional Chinese medicine. In depth discussions have been conducted, providing cutting-edge information for traditional Chinese medicine researchers and entrepreneurs who adhere to integrity and innovation, and injecting new innovative momentum into the Chinese traditional Chinese medicine industry.

Chairman Zhang Min of Mengyang Pharmaceutical was invited to participate in a closed door meeting on how to strengthen technological support, talent support, enhance technological innovation and achievement transformation capabilities, and promote the inheritance and innovation of traditional Chinese medicine. He shared Mengyang Pharmaceutical's experience with the leaders and experts present.

Academician Chen Kaixian, Professor Lin Ge from the Chinese University of Hong Kong, Professor Wang Xijun, Director of the National Key Laboratory of Heilongjiang University of Traditional Chinese Medicine, Professor Kong Lingyi, Vice President of China Pharmaceutical University, Researcher Sun Xiaobo from the Institute of Medicinal Plants of the Chinese Academy of Medical Sciences, Professor Chen Shilin from Chengdu University of Traditional Chinese Medicine, and Researcher Xiao Xiaohe, Director of the Institute of Traditional Chinese Medicine of the whole army A group of experts and scholars, including researcher Yuan Yuan from the Traditional Chinese Medicine Resource Center of the Chinese Academy of Traditional Chinese Medicine, shared their research achievements in their respective fields at the academic exchange meeting, which greatly benefited everyone. The meeting also arranged high-end exchange sessions, where Professor Zhang Weidong from Naval Medical University, Dean Zhang Junhua from Tianjin University of Traditional Chinese Medicine, Researcher Zhang Baoxian from the Chinese Academy of Traditional Chinese Medicine, Professor Liu Jianxun from Xiyuan Hospital of the Chinese Academy of Traditional Chinese Medicine, Dean Ma Xiaohui from Tianshili Research Institute, and Chairman Xiao Junping from Jiangxi Puzheng Pharmaceutical Co., Ltd. shared their valuable experiences and profound insights on "Strategies and Challenges in the Development of New Chinese Medicine".

In the academic exchange section of the conference, Dr. Huang Qian, Vice President of R&D at Mengyang Pharmaceutical, gave a brilliant presentation on the development of innovative drugs derived from Schisandra chinensis. She mentioned that adriamycin is the main treatment drug for lymphoma, breast cancer, soft tissue sarcoma and other malignant tumors. Cardiotoxicity is considered the most serious toxic side effect of doxorubicin, which seriously affects the treatment of patients and endangers their health. DH001 is an innovative drug developed by Mengyang Pharmaceutical, which purifies traditional Chinese medicine Schisandra chinensis. Pharmacodynamic studies have shown that DH001 can prevent and treat acute and chronic cardiotoxicity caused by doxorubicin, significantly improving the survival rate of animals. It can be taken before chemotherapy and has the characteristic of combining prevention and treatment. In addition, DH001 has good overall safety and tolerability, possesses certain anti-tumor activity, and has the advantages of convenient use and moderate price, which can reduce the burden on patients. Currently, a randomized, double-blind, multicenter phase II clinical study is being conducted to preliminarily evaluate the safety and efficacy of DH001 in cancer patients. DH001 is expected to become the first orally administered drug to prevent doxorubicin induced cardiac toxicity.

Based on the listed products and years of research and development accumulation, Mengyang Pharmaceutical is committed to improving the quality of life of cancer patients and becoming a leader in the field of cancer treatment related diseases. Mengyang Pharmaceutical will leverage its corporate advantages, continuously explore and research, closely collaborate, and strive to develop classic formulas of renowned traditional Chinese medicine and effective ingredients derived from natural medicines into new drugs. It will integrate traditional Chinese medicine and Western medicine for innovation, inherit the wisdom of traditional Chinese medicine, extract the essence of Western medicine, and contribute to the contemporary cancer prevention and treatment industry.